122 related articles for article (PubMed ID: 10516346)
1. Pharmacokinetics of intraperitoneal epoetin alfa in patients on peritoneal dialysis using an 8-hour "dry dwell" dosing technique.
Taylor CA; Kosorok MR; Zimmerman SW; Johnson CA
Am J Kidney Dis; 1999 Oct; 34(4):657-62. PubMed ID: 10516346
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetics of intraperitoneal, intravenous, and subcutaneous recombinant human erythropoietin in patients on continuous ambulatory peritoneal dialysis.
Ateshkadi A; Johnson CA; Oxton LL; Hammond TG; Bohenek WS; Zimmerman SW
Am J Kidney Dis; 1993 Jun; 21(6):635-42. PubMed ID: 8503418
[TBL] [Abstract][Full Text] [Related]
3. Comparison of intraperitoneal and subcutaneous epoetin alfa in peritoneal dialysis patients.
Johnson CA; Wakeen M; Taylor CA; Zimmerman SW; Burkart J; Bhattacharya A; Kosorok MR
Perit Dial Int; 1999; 19(6):578-82. PubMed ID: 10641779
[TBL] [Abstract][Full Text] [Related]
4. National cooperative rHu erythropoietin study in patients with chronic renal failure: a phase IV multicenter study. Report of National Cooperative rHu Erythropoietin Study Group.
Nissenson AR
Am J Kidney Dis; 1991 Oct; 18(4 Suppl 1):24-33. PubMed ID: 1928075
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetics of intermittent intraperitoneal cefazolin in continuous ambulatory peritoneal dialysis patients.
Manley HJ; Bailie GR; Asher RD; Eisele G; Frye RF
Perit Dial Int; 1999; 19(1):65-70. PubMed ID: 10201343
[TBL] [Abstract][Full Text] [Related]
6. The pharmacokinetics of intraperitoneal erythropoietin administered undiluted or diluted in dialysate.
Bargman JM; Jones JE; Petro JM
Perit Dial Int; 1992; 12(4):369-72. PubMed ID: 1420495
[TBL] [Abstract][Full Text] [Related]
7. Intraperitoneal erythropoietin in children on peritoneal dialysis: A study of pharmacokinetics and efficacy.
Kausz AT; Watkins SL; Hansen C; Godwin DA; Palmer RB; Brandt JR
Am J Kidney Dis; 1999 Oct; 34(4):651-6. PubMed ID: 10516345
[TBL] [Abstract][Full Text] [Related]
8. Subcutaneous erythropoietin results in lower dose and equivalent hematocrit levels among adult hemodialysis patients: Results from the 1998 End-Stage Renal Disease Core Indicators Project.
McClellan WM; Frankenfield DL; Wish JB; Rocco MV; Johnson CA; Owen WF;
Am J Kidney Dis; 2001 May; 37(5):E36. PubMed ID: 11325701
[TBL] [Abstract][Full Text] [Related]
9. Intravenous versus subcutaneous dosing of epoetin alfa in hemodialysis patients.
Paganini EP; Eschbach JW; Lazarus JM; Van Stone JC; Gimenez LF; Graber SE; Egrie JC; Okamoto DM; Goodkin DA
Am J Kidney Dis; 1995 Aug; 26(2):331-40. PubMed ID: 7645538
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetics of 300 mg/d Intraperitoneal Daptomycin: New Insight from the DaptoDP Study.
Saint Paul LP; Ficheux M; Debruyne D; Loilier M; Bouvier N; Morello R; Verdon R; Le Blanc E; Cattoir V; Lobbedez T
Perit Dial Int; 2018; 38(6):463-466. PubMed ID: 30413641
[TBL] [Abstract][Full Text] [Related]
11. An open-label, randomized, multicenter, controlled study of epoetin alfa for the treatment of anemia of chronic kidney disease in the long term care setting.
Patel M; Thimons DG; Winston JL; Langholff W; McGowan T
J Am Med Dir Assoc; 2012 Mar; 13(3):244-8. PubMed ID: 21450214
[TBL] [Abstract][Full Text] [Related]
12. Australian haemodialysis patients on intravenous epoetin alfa or intravenous darbepoetin alfa: how do they compare?
Pussell BA; Walker R;
Nephrology (Carlton); 2007 Apr; 12(2):126-9. PubMed ID: 17371333
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetics and pharmacodynamics of epoetin delta in two studies in healthy volunteers and two studies in patients with chronic kidney disease.
Smith WB; Dowell JA; Pratt RD
Clin Ther; 2007 Jul; 29(7):1368-80. PubMed ID: 17825688
[TBL] [Abstract][Full Text] [Related]
14. The predictive parameters of erythropoietin hyporesponsiveness in patients on continuous ambulatory peritoneal dialysis.
Kim JK; Park BS; Park MJ; Choi W; Ma SK; Nah MY; Yeum CH; Jung K; Lee SC; Kim SW; Kim NH; Kang YJ; Choi KC
Korean J Intern Med; 2001 Jun; 16(2):110-7. PubMed ID: 11590897
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetics of recombinant human erythropoietin in patients on continuous ambulatory peritoneal dialysis.
Macdougall IC; Roberts DE; Neubert P; Dharmasena AD; Coles GA; Williams JD
Lancet; 1989 Feb; 1(8635):425-7. PubMed ID: 2563798
[TBL] [Abstract][Full Text] [Related]
16. Comparative pharmacokinetics of recombinant erythropoietin administered by the intravenous, subcutaneous, and intraperitoneal routes in continuous ambulatory peritoneal dialysis (CAPD) patients.
Boelaert JR; Schurgers ML; Matthys EG; Belpaire FM; Daneels RF; De Cre MJ; Bogaert MG
Perit Dial Int; 1989; 9(2):95-8. PubMed ID: 2488207
[TBL] [Abstract][Full Text] [Related]
17. Extended epoetin alfa dosing as maintenance treatment for the anemia of chronic kidney disease: the PROMPT study.
Provenzano R; Bhaduri S; Singh AK;
Clin Nephrol; 2005 Aug; 64(2):113-23. PubMed ID: 16114787
[TBL] [Abstract][Full Text] [Related]
18. Intraperitoneal recombinant human erythropoietin therapy: influence of the duration of continuous ambulatory peritoneal dialysis treatment and peritonitis.
Huang TP; Lin CY
Am J Nephrol; 1995; 15(4):312-7. PubMed ID: 7573189
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetics of intraperitoneal cefepime in automated peritoneal dialysis.
Elwell RJ; Frye RF; Bailie GR
Perit Dial Int; 2005; 25(4):380-6. PubMed ID: 16022096
[TBL] [Abstract][Full Text] [Related]
20. Systemic absorption of intraperitoneal antimicrobials in continuous ambulatory peritoneal dialysis.
O'Brien MA; Mason NA
Clin Pharm; 1992 Mar; 11(3):246-54. PubMed ID: 1611814
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
